1[1]Zadina JE,Hackler L,Ge LJ,et al.A potent and selective endoge nous agonist for the μ-opiate receptor.Nature,1997,386:499-502
2[2]Stone LS,Fairbanks CA,Laughlin TM,et al.Spinal analgesic ac tions of the new endogenous opioid peptides endomorphin-1 and -2.Neuroreport,1997,8:3131-5
3[3]Claude PA,Wotta DR,Zhang XH,et al.Mutation of as conserved serine in TM4 of opioid receptors confers full agonist properties to classical antagonists.Proc Natl Acad Sci USA,1996,93:5715-9
4[4]Crain SM,Shen K-F.Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opi oid tolerance / dependence liability.Pain,2000,84:121-31
6[8]Sharma AC,Misra M,Prat R,et al.A differential respedothelin and nitric oxide in the plasma and brain regions in rats.Neurol Res,1998,20(7):632
7[9]Nicoj B,Lambert DG,Rowbotham DJ.et al.Nocieptin induced inhibition of K evoked glutamate release from rat cerebrocori.cals1ices.B J pharmacol,1996,119(6):1081-1083
8[10]Nisbi M,Houtani T,Noda Y,et al.Unrestrained nOcicptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor EMBOJ,1997,16(8):1858-1864
9[11]GintzlerAR,AdapaID,T oll L,et al.Modulation of enkephalm re lease by nociceptin(orphanin FQ)Eur J Pharmacol,1997,325(1):29-34
4Gentile NT,Mclntosh TK. Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous system injury[J]. Ann Emerg Med,1993. 22: 1028-1034.
5Lai SLGu Y,Huang LY. Dynorphin uses a non-opioid mechanism to potentiate N-methyl-D-aspartate currents in single rat periaqueductal gray neurons[J].Neurosci Lett,1998, 247:115-118.
6Hohzman DM, Sheldon RA, Jaffe W, et al. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury[J].Ann Neurol, 1996, 39: 114-122.
7Mclntosh TK,VinkR, Noble L, et al.Traumatic brain injury in the rat: characterization of a lateral fluid-percussion model[J].Neuroscience 1989,28:233-244.
8Ohkawa H,Ohishi N,Yagi K.Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction [J].Anal Biochem,1979,95:351-358.
9Hauser KF,Foldes JK,Turbek CS.Dynorphin A(1-13)neurotoxicity in vitro:opioid and non-opioid mechanisms in mouse spinal cord neurons[Jl.Exp Neurol,1999,160:361-375.
10Malan TP,Ossipov MH,Gardell LR,et al. Extraterritorial neuropathic pain correlates with muhisegmental elevation of spinal dynorphin in nerve-injured rats[J].Pain,2000,86:185-194.
4Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol, 2003, 35(7): 709-718.
5Fryer RM, Pratt PF, Hsu AK, et al. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther, 2001, 296(2) : 642-649.
6Zhang Y, Irwin MG, Wong TM, et al. Remifentanil preconditioning confers cardioprotection via cardiac kappa-and delta-opioid receptors. Anesthesiology, 2005, 102(2): 371-378.
7Lasukova TV, Maslov LN, Platonov AA, et al. The effect of stimulation of cardiac deltal -opioid receptors on the resistance of isolated heart to the action of ischemia and reperfusion. Eksp Klin 17armakol, 2005, 68(6): 19-24.
8Guo Y, Stein AB, Wu WJ, et al. Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and deltal-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Cire Physiol, 2005, 289(5 ) : H2251 -H2257.
9Patel HH, Head BP, Petersen HN, et al. Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and $-opiold receptors. Am J Physiol Heart Circ Physiol, 2006, 291(1): H344-H350.
10Fodale V, Schifilliti D, Pratici C, et al. Remifentanil and the brain. Acta Anaesthesiol Scand, 2008, 52 (3) : 319 -26.
